By Jonah Comstock, MobiHealth News | October 25, 2018
Over the quarter, MobiHealthNews tracked $3.3 billion in digital health deals.
MobiHealthNews tracked 71 digital health funding deals in Q3 2018, totally $3.3 billion in investment (coincidentially, the same number Rock Health came up with). Both Rock Health and Startup Health have pegged this quarter as the biggest ever for digital health investment, so we’ve rounded up the deals so readers can take a deep dive into the makeup of this landmark quarter.
The list is organized in descending order of deal size, with Peloton’s $550 million Series F and Oscar’s $375 million infusion from Alphabet leading off. For each entry, we’ve listed what the company plans to do with the funding, sourced from interviews or press releases at the time of the raise, and a brief overview of what the company does. To dig even deeper, click the company name to visit our original reporting on the raise.
| Company | Round/Series | Amount | Investors | What’s it for | What they do |
|---|---|---|---|---|---|
| Peloton | Series F | $550M | TCV (lead), Tiger Global, True Ventures, Wellington Management, Fidelity, NBCUniversal, Kleiner Perkins, Balyasny, Felix Capital, Winslow Capital, other unnamed mutual fund partners | The new funding will allow Peloton to expand into additional international markets, and will also be used for “general corporate purposes” such as providing liquidity to existing shareholders. | Peloton’s primary consumer offering is an exercise bike integrated with a tablet-like screen. With this, users can join in live or pre-recorded classes with on-staff cycling instructors. Earlier this year the company also launched an app-based digital subscription service offering many of these live and pre-recorded fitness features, and will soon be releasing a connected home treadmill similar to its primary exercise bike offering. |
| Oscar Health | strategic | $375M | Alphabet | The Alphabet investment will be used to accelerate Oscar Health’s ongoing business model. | Oscar Health’s strategy involves engaging members in their care using a virtual, personalized platform. With this, the company guides its members toward more affordable care options while, on the provider side, offering operational integrations and easy-to-use tools for major health system partners. |
| American Well | Series C | $365.4M | Undisclosed | American Well didn’t comment on the funding, but at HIMSS18, Dr. Ido Schoenberg, American Well co-CEO, said the company has been laying the groundwork to pull back from video visits and establish itself more broadly as a connector technology that will help various stakeholders in healthcare work together remotely. | American Well offers telemedicine services to systems, plans, employers and other customers. |
| 23andMe | strategic | $300M | GlaxoSmithKline | Anne Wojcicki, CEO and cofounder of 23andMe, characterized the investment as “transformative” for her company and noted that it “will enable us to deliver on what many customers have been asking for — cures or treatments for diseases.” | 23andMe offers genomic testing directly to consumers. It also leverages these data for medical research, as well as for sale to pharmaceuticals and others. |
| Butterfly Health Network | Series D | $250M | Fidelity (lead), Fosun Pharma, Bill & Melinda Gates Foundation, Jamie Dinan, other existing investors | The new funds will be put toward finally shipping its flagship product. | The company is developing a sub-$2,000, handheld, tablet-connected full-body ultrasound device, called the Butterfly IQ. |
| Jianke Pharmaceutical | Series B | $130M | GTJA Investment Group (lead), HMB Healthcare Investments, Crescent Point participating | This announcement comes ahead of the company’s US IPO, which is planned for next year. | Jianke Pharmaceutical is a Chinese online pharmacy retailer that sells its medications directly to consumers. |
| Ro | Series A | $88M | FirstMark Capital (lead), SignalFire, Initialized Capital, General Catalyst, Slow Ventures, Sinai Ventures, Torch Capital, BoxGroup, Tusk Ventures, undisclosed angel investors | Ro will primarily be putting these funds into a new addiction cessation platform, called Zero. | The core of Ro, previously Roman, is an erectile dysfunction platform heavily reliant on remote consultation and mail-order treatments. |
| ClassPass | Series D | $85M | Temasek (lead), L Catterton’s Growth Fund | ClassPass is looking to expand its platform within new and existing global markets. | The fitness membership platform users to opt into one membership and then access workout classes at various locations. It also gives members access to workout videos and blogs, and has the ability to connect people through the app. |
| Clarify Health Solutions | Series B | $57M | KKR | This new funding will help Clarify expand its clinical, sales, engineering, and data science teams, according to the announcement. It will also allow the company to obtain and incorporate additional data while furthering development of its digital platform. | Clarify Health Solutions (not to be confused with phototherapy company Clarify Medical) offers a digital platform that incorporate predictive analytics and machine learning into the design of care delivery models. Boasting a 20 terabytes of clinical, claims, social determinant, lab, and prescription with which to make its inferences, the company’s offerings help match patients to appropriate and cost-effective care. |
| Hims | Series B | $50M | Institutional Venture Partners (lead), Forerunner Ventures, Redpoint Ventures and Thrive Capital | The new funding will be used to scale the Hims platform, with special emphasis on expanding its prescription drug business. | Hims discretely sends men’s health products and medications through the mail after customers receive their prescriptions through remote consultation. |
| InfoBionic | unknown | $50M | Eagle Investments, Excel Venture Management, Safeguard Scientifics, Zaffre Investments, Blue Cross and Blue Shield of Kansas | InfoBionic plans to use the funding to expand commercialization of the platform. | The company’s main product is the MoMe Kardia system. It is designed to help detect cardiac arrhythmias in patients by sensing ECG, respiration, and motion. The lightweight monitoring device can be worn as a necklace or belt attachment. |
| MDLive | N/A | $50M | Health Velocity Capital (lead), Cigna Corporation, Health Care Service Corporation, Novo Holdings A/S, Industry Ventures | The new funding will be used to “accelerate the development growth of our existing service offerings,” according to MDLive CEO Rich Berner. | MDLive’s provides its telehealth services to 27 million Americans. Currently its healthcare services include certified doctors, counselors, psychiatrists, and dermatologists, although the company is now looking to grow in the field of proactive and predictive care. |
| Capsule | Series B | $50M | Thrive Capital, Brook Capital Partners | Capsule hopes to use the funding to expand its New York-based business to the national market. | An online pharmacy and delivery service, the company promises to deliver the medication to anyone in New York City within two hours of the interaction. The platform also lets patients transfer their refills from their old pharmacies to Capsule. |
| League | Series B | $47.5M | Telus Ventures (lead), Wittington Ventures, Omers, Infinite Potential Group, RBC Ventures, Real Ventures, BDC Ventures | The new money is expected to help the company grow internationally and establish new offices in San Francisco, New York, and London. Up next, the company has its eyes on the UK and EU. | League pitches itself as a platform that makes benefits easier to navigate and is “consumer centric.” Customers can customize health plans to fit different needs and include reward programs. |
| Profusa | Series C | $45M | VMS Investment Group, Tasly Pharmaceutical Group Maxim Integrated, 3E Bioventures Capital, Atinum Investment | The company will be using the new financing to bring its CE Marked sensor, the Profusa Lumee Oxygen Platform, toward commercialization and continue development of another continuous biosensor focused on glucose detection. | Profusa develops connected tissue-implanted biosensors able to deliver real-time, clinical-grade biochemical information. |
| Endotronix | Series D | $45M | LSP (lead), Aperture Venture Partners, BioVentures Investors, Lumira Ventures, OSF Ventures, Seroba Life Sciences, SV Health Investors, Wanxiang Healthcare Investments, unnamed corporate investor | The new money is going to be used to launch Cordella Heart Failure System, which is made up of a wireless pulmonary artery sensor and a cloud-based outpatient management system. It will also help push the Cordella Pulmonary Artery Sensory system through the FDA process. | Endotronix’s business is focused on heart failure management and remote monitoring devices. |
| Ooda Health | Series A | $40.5M | Oak HC/FT, DFJ, (leads) Anthem, Blue Cross Blue Shield of Arizona, Blue Shield of California, Zaffre Investments, Dignity Health, Hill Physicians | The series will be used to grow and build Ooda’s fledgling business. | Ooda Health’s vision is to use technology to connect the healthcare consumer, payer, and provider, creating a consumer experience that’s more like other retail transactions and a more collaborative, efficient back-end communication between payers and providers. |
| Nurx | Series B | $36M | Kleiner Perkins Caufield & Byers (lead), Union Square Ventures, Y Combinator, Lowercase Capital | The company will use the funding to continue to expand its offering into more states. | Nurx’s app and website uses telemedicine to connect rural patients to contraceptives. |
| Centivo | Series A | $34M | Bain Capital Ventures (lead), F-Prime Capital Partners, Maverick Ventures, Bessemer Venture Partners, Ingleside Investors, Rand Capital, Grand Central Tech Ventures, Oxeon Investments, individual investors including Jim Foreman, Ken Goulet, Kevin Hill | The funding will be used to support the launch of Centivo’s full platform in New York, New Jersey, Connecticut and other select markets. | Centivo’s outcome-focused health plan model focuses on better connecting patients with primary care providers. Offered through employer customers, the health plan also aims to incentivize members to seek appropriate, cost-effective care and maintain adherence to their personal care plans. |
| IDx | Series A | $33M | 8VC (lead), Optum Ventures, Alpha Edison, Heritage Provider Network | The company plans to use the money to further develop additional diagnostic systems for its AI platform, as well as commercialize its diabetic retinopathy tool. Specifically the startup is looking into AI diagnostics for age related eye conditions. | IDx makes an autonomous AI diagnostic tool for diabetic retinopathy, called IDx-DR. |
| Olive | Series D | $32.8M | Oak HC/FT, Ascension Ventures | The company plans to use the new money scale its AI technology and invest in new capabilities, such as its process mining tool Pupil. | Olive is a healthcare software company that employs artificial intelligence to automate provider workflows. |
| Renovia | Series B | $32.3M | Perceptive Advisors, Ascension Ventures (leads), Longwood Fund, Inova Strategic Investments, Cormorant Asset Management, OSF Ventures, Western Technology Investment | The new backing will be put toward clinical trials, corporate development, development of the company’s product pipeline, and supporting upcoming commercial launches. | Renovia’s flagship product is the leva Pelvic Digital Health System, which is comprised of a smartphone app and connected probe. Sold alongside another device, the EmbaGYN Pelvic Floor Exerciser, the company’s offering guides users through training sessions to strengthen the muscles necessary to maintain continence while collecting compliance and progress data for later use. |
| Startup Health | N/A | $31M | Novartis, Ping An Group, Chiesi Group, GuideWell, Otsuka, Masimo, other private investors | The latest funding will be invested into its Transformer Fund II, which will invest in and support companies that are focused on the moonshot goals. | StartUp Health works with young digital health companies by coaching, mentoring, and helping them to network. Currently the company is working on 10 initiatives, which it calls moonshots, that include ending cancer, supporting brain health, and improving access to care. |
| Evidation Health | Series C | $30M | SV Health Investors, B Capital Group (lead), GE Ventures, Sanofi Ventures | The funding will support the launch of a new platform that marries smartphone, sensor, and medical data together for cohesive insights into patient behaviors and outcomes. | Evidation Health works with payers, pharma companies, healthcare systems, and vendors of digital health solutions. The company combines real-life patient data from collected through more than 100 different sources — Apple Health, Fitbit, Epic, and Dexcom, to name a few — to assess care or specific interventions. |
| Verana Health (formerly DigiSight) | Series C | $30M | GV, Biomatics Capital, Brook Byers (founder of Kleiner, Perkins, Caufield & Byers), GE Ventures, and Lagunita Biosciences | With the fresh $30 million, the company is looking for additional datasets and professional organizations to extend the model out to a few additional specialties. They also intend to use some of the funds to grow the team around the company’s new focus. | Formerly a tele-ophthalmology company, Verana Health is now focusing on commercializing healthcare datasets, starting with the IRIS dataset. |
| Care/of | Series B | $29M | Goldman Sachs Investment Partners (lead), Goodwater Capital, Juxtapose, RRE Ventures, Tusk Ventures, Beth Kaplan, and Doug Hudson | Care/of says in plans to use the funding “to grow beyond its core vitamin offering towards a broader vision of a truly personalized and holistic health and wellness experience.” | The way the platform works is customers first fill out an online questionnaire about their goals, lifestyle, and values. The platform will then give users recommendations about which vitamins and supplements would work best for that person. Customers then get personalized daily packs of vitamins and supplements. |
| Maven | Series B | $27M | Oak HC/FT (lead), Spring Mountain Capital, 14W, Female Founders fund | The new money will be used to help expand its return-to-work care products, including a new breastmilk shipping service. | The digital health platform was first founded in 2014 and is focused on linking women and families to providers. It also helps users book video appointments and send messages to services including health practitioners, OB-GYNs, midwives, therapists, and nutritionists. |
| Potrero Medical | Series C | $26.6M | GT Healthcare Capital Partners, Sonder Capital | The new funding will be used to develop an artificial intelligence and data analytics platform that would work alongside the Accuryn system to to facilitate early interventions prior to life-threatening events such as acute kidney injury. | Potrero’s business is focused on employing smart sensors and data analytics to identify conditions in their early stages. Its primary product is the Accuryn Monitoring System, a sensor-laden replacement for traditional urinary catheters that monitors vitals. |
| Hinge Health | Series B | $26M | Insight Venture Partners, Atomico | The company plans to use the new funding to build out its sales and R&D teams, both to meet demand for its existing product and to develop offerings for additional musculoskeletal conditions. | Hinge Health offers employers a three-part benefits program for musculoskeletal patients that includes app-based exercise therapy using wearable sensors, unlimited virtual coaching, and interactive patient education. |
| Mirror | Series B | $25M | Spark Capital | The funding will support the launch of the Mirror device, which began shipping in early September. | Mirror makes an in-home virtual workout product for consumers. The device streams workout videos and music on demand through its large LCD panel, which also serves as a full-length mirror when not in use. |
| Cricket Health | Series A | $24M | Oak HC/FT | The money is expected to be used to help expand Cricket Health’s tech-enabled programs. | The company aims to identify patients at risk of kidney failure in order to preserve kidney function as long as possible. The technology works both remotely and in a clinical setting. It provides patients with education and 24-7 peer and clinical support. |
| higi | Series A | $21.3M | Flare Capital Partners, 7wireVentures | This latest funding round is expected to help the company expand access points to consumers and increase user engagement. | The technology allows users to go to a higi kiosk and request a number of different tests measuring blood pressure, pulse, weight, and BMI. Currently there are 11,000 FDA-cleared higi kiosk stations around the country. The company also has an app that it launched in 2015, which lets consumers keep track of their step and biometric data on their phone. Through the app, users can also follow friends and set goals. |
| Viz.ai | Series A | $21M | Kleiner Perkins, GV | The company will be using its new backing to expand its offering into new markets, and to extend its product portfolio to conditions outside of stroke. | Viz.ai’s primary product is Contact, the first FDA-cleared clinical decision support (CDS) tool that analyzes CT results and highlights cases that may have experienced a stroke for review by a neurovascular specialist. |
| Click Therapeutics | Series A | $17M | Sanofi Ventures | The latest funding is expected to help the company work on its proprietary platform and the pipeline of its digital therapeutics. | Currently the New York-based company is working on digital prescription therapeutics for depression, insomnia, acute coronary syndrome, and chronic pain. The plan is to go through the FDA process and get clearance for these software programs as Class 2 medical devices. |
| CareStack | Series B | $16M | Accel, F-Prime Capital Partners, Eight Roads Ventures | The funding will be used to support the opening of the company’s new office in Cambridge, Massachusetts. | CareStack’s cloud-based platform manages dental offices clinical, financial, and administrative workflows. |
| Carbyne | Series B | $15M | Elsted Capital Partners (lead), Founders Fund | Carbyne will be using these new funds to build its presence in global markets and fuel R&D. | Carbyne develops an end-to-end, digitized emergency response system designed to help emergency response personnel better handle incoming calls. |
| Naked Labs | Series A | $14M | Founder’s Fund (lead), NEA, Lumia Capital, Venture 51, Seabed VC | The company will use the funding to support the launch of its first product, the Naked 3D Fitness Tracker. | The Naked 3D Fitness Tracker is a WiFi-enabled mirror that has built-in infrared sensors and communicates with a turntable scale. When a user steps onto the scale, which activates the mirror, the scale rotates the user 360 degrees to create a body scan. The tracker measures the user’s body fat percentage and weight and scans their body using Intel RealSense technology. |
| AlayaCare | Series B | $13.8M | Inovia capital (lead), Chrysalis, Fonds Innovexport | The funding will be used for R&D, to accelerate the company’s product roadmap. | Focused on providing home healthcare workers and clients with tools, the company’s software has several different platforms including a mobile app and clinical documentation tool. |
| Notable | Series A | $13.5M | F-Prime Capital Partners, Oak HC/FT (leads), Greylock Partners, Maverick Ventures | The company said that it plans to use the new money to fund the expansion of its AI platform. The platform’s AI technology learns doctors’ behaviors and can, in turn, help with billing and coding. | This news comes just months after Notable launched its latest product, a voice-powered artificial intelligence wearable for doctors. The platform combines AI and voice recognition technology to capture information from a doctor’s visit. |
| Akili Labs | add on to Series C | $13M | CLSA, Omidyar Technology Ventures, Digital Garage Group, Fearless Ventures | The additional investment will be used to support development and deployment Akili’s digital therapeutics, one of which is currently under review by the FDA. | Akili develops prescription digital treatments that are delivered through video game experiences. |
| K Health | unknown | $12.5M | Mangrove Capital Partners, Lerer Hippeau, Primary Venture Partners, BoxGroup, Max Ventures, Bessemer Venture Partners, Comcast Ventures | The funding supports the launch of the company’s free primary care app. Called K, the app’s AI references a history of diagnoses and treatments to deliver users an insight about how their condition would likely be treated, and can also connect users (in the New York City area) to a network of primary care providers. | K Health looks to give healthcare consumers a chance to benefit from big data. Using a dataset comprised of more than 1 billion physician notes, lab results, treatments, prescriptions, and other interactions, the company’s AI informs users about how their health issue has been diagnosed and treated in the past. With this, consumers have a rough idea of their issue’s severity, and if necessary can be connected with a primary care physician. |
| Klara | Series A | $11.5M | FirstMark Capital (lead) , Lerer Hippeau, Project A Ventures, Atlantic Labs, other individual investors | Klara plans to use the new money to improve its automation, user experience design, and integration into workflows. | Klara’s digital healthcare communications platform connects patients with care teams. It lets users send messages, lab results, and photos of patients, and all of the information can be exported to the patient’s EHR. |
| Lumiata | Series B | $11M | Khosla Ventures, BlueCross BlueShield Venture Partners (lead), Sandbox Industries, Intel Capital, other unnamed investors | The new backing will primarily be used to accelerate deployment of the company’s health analytics offering. | Lumiata’s analytics offering works with health plans and providers to identify at-risk patients and manage costs. According to the company, its models have so far been used to predict risk or chronic condition onset for more than 20 million patient lives. |
| CyberMDX | Series A | $10M | Pitango Venture Capital (lead), OurCrowd Qure | The company will be using the new funding to support its product and R&D teams, scale its product, and grow its presence in North America while expanding to new markets. | CyberMDX, a connected medical device and clinical network security firm, is non-intrusive, and doesn’t apply any software within the protected devices themselves. |
| Proscia | Series A | $8.3M | Flybridge Capital Partners (lead), Emerald Development Managers, Fusion Fund, Razor’s Edge Ventures, RobinHood Ventures | The Philadelphia-base startup plans to use the new money to commercialize its digital pathology software and speed up the use of its AI applications for cancer diagnosis. Additionally, the new funding will finance the development of an AI workflow tool, that will focus on high impact cancers. | The company has previously rolled out a cloud-based digital pathology platform, which enables hospitals create new image-based workflows to streamline operations, open new imagining and analytics revenue streams, and aid diagnostics. |
| Peerfit | unknown | $8M | Ark Applications, PAR (leads), Causeway Media Partners | The funding is expected to support additional growth. | Peerfit’s benefits platform allows companies to offer their employees access to a network of participating fitness studios. Employees receive credits which can be redeemed for classes of various skill levels. |
| Sansoro Health | Series B | $8M | LRVHealth (lead), Bain Capital Ventures, Healthy Ventures | The company said that this latest funding will be used to help speed up the evolution of its new platform Emissary, an API software platform, designed to help digital health apps integrate with EHRs. | Sansoro Health is a healthcare integration company focused on interoperability. |
| Sempre Health | Series A | $8M | Rethink Impact (lead), Social Capital, other unnamed backers | With these new funds, the company said it will be working to flesh out its network of partners. | To encourage care adherence, Sempre works with a range of stakeholders including payers, pharmaceutical manufacturers, and pharmacy benefit managers. Its platform can inform patients about discounts on their prescriptions, and change those discounts to incentivize more healthy behaviors. |
| snap40 | seed | $8M | ADV (lead), MMC Ventures, other private investors. | snap40 plans to use the money to expand further in the US. It reports already having pilots and clinical trials with US hospitals and institutions. | snap40’s offering is a system that monitors patients using a unique wearable device that employs AI and can alert clinicians if a patient’s condition is deteriorating. The company claims the system is equivalent to ICU monitoring. |
| SkinVision | Series B | $7.6M | Leo Pharma, PHS Fund | SkinVision will also use the funding to move toward an FDA submission in preparation for a US launch. | While SkinVision is working towards primarily offering its AI-powered skin cancer screening service via insurance providers, they also offer a direct-to-consumer option that has helped them to train their algorithms. |
| HealthCrowd | Series A | $7.2M | TVC Capital, Startup Capital Ventures, Healthy Ventures | The funding will be used to support growth. | HealthCrowd makes an enterprise platform for digital patient communications and analytics. |
| SnapMD | Series B | $7.1M | Existing investors | The funding will be used to support marketing and business development to grow SnapMD’s provider base. | Enterprise telehealth company SnapMD provides a variety of white-labeled virtual care tools to hospitals. |
| Spring Health | seed | $6M | Rethink Impact (lead), Work-Bench, BBG Ventures, The Partnership Fund for New York City, RRE Ventures, William K. Warren Foundation | The company will be using its new funding to expand its product and scale the offering nationwide. | Spring Health is a digital wellness platform that connects employees to mental healthcare resources. |
| Beddr | Series A | $5.6M | Three Leaf Ventures (lead), Stanford-StartX Fund, Delta Dental Washington Seed Fund, IT Farm, other unnamed individuals | Beddr has used the new money to commercialize and push its clinical-grade consumer sleep tracker to market. | Beddr’s SleepTuner is a tracker roughly the size of a quarter that is attached to the user’s forehead with one-time use hypoallergenic adhesives. Along with sleep duration, the device gauges sleep quality by tracking sleeping position, heart rate variance, blood oxygen saturation, and stopped breathing events. |
| Kindly Care | Series A | $5.4M | Javelin Venture Partners | The company plans to use the money to expand the product offerings and support national expansion. | The senior care startup offers an alternative to going through a traditional home agency. Instead, customers can use the platform to search for caregivers that have already undergone background checks. |
| Wellth | Series A | $5.1M | Boehringer Ingelheim’s Venture Fund, NFP’s Venture Fund (lead), Leonard Schaeffer, CD-Venture, the Partnership Fund for New York City, Yabeo | The company plans to use the funding to identify and pursue new opportunities and partners. | Wellth teams up with insurers and risk-based providers to give patients financial incentives for taking their medications and engage in healthy behaviors. The platform caters to patients with heart failure, Type 2 diabetes, COPD, and asthma, as well as patients who have recently been discharged from the hospital following a heart attack. |
| Nebula Genomics | seed | $4.3M | Khosla Ventures, Arch Venture Partners, Fenbushi Capital, Mayfield Fund, F-Prime Capital Partners, Great Point Ventures, Windham Venture Partners, Hemi Ventures, Mirae Asset, Hikma Ventures, Heartbeat Labs | Nebula Genomics will use the funding to build and scale its blockchain-based genomics platform. | Nebula’s plan is to sequence a participant’s DNA for no out-of-pocket cost. People can then sell their data to researchers and receive Nebula tokens in exchange. A user is able to use these coins to purchase information about their genome sequencing and what it means in terms of their, and their future children’s, health. |
| Oxford VR | unkown | $4.11M | Oxford Sciences Innovation, University of Oxford, Force Over Mass, RT Capital, GT Healthcare Capital Partners | The Oxford University spinout plans to use the new money to grow its VR platform and bring the technology to market. | Oxford VR develops VR applications to treat mental health conditions. It has been deployed in select NHS locations, and featured in a Lancet Psychiatry study studying the effectiveness of virtual coaching therapy. |
| aktiia | seed | $4.1M | TransLink Capital and Redalpin (leads), Sparks Street Capital, Christian Wenger, Mladen Barbaric | The latest funding will help staff develop and validate its product. | The company is in the process of developing a continuous blood pressure monitoring bracelet designed to help patients with hypertension. |
| Fit4D | unknown | $4M | SJF Ventures, C&B Capital, Esther Dyson, and North Haven Capital (leads), Blue Cross and Blue Shield of Nebraska, StartUP Health | The New York City-based startup plans to use the money to continue clinical validation and development of its product. | Digital diabetes coaching platform Fit4D was designed so that diabetes patients could more easily get access to a Certified Diabetes Educator (CDE) for one-on-one coaching. The company markets itself as a scalable way for people to get more personalized coaching, filling in the gaps of traditional care. |
| Healthera | Series A | $3.8M | Accelerated Digital Ventures (lead), Cambridge Enterprise, Future Care Capital | Healthera intends to use the funds to accelerate its expansion across the UK and ‘triple the size of [its] commercial force’, according to Managing Director Martin Hao. | Healthera’s offering, already listed on the NHS Digital Apps Library, enables patients to track their prescriptions, monitor medication intake, and access clinical services, connecting more than 800 pharmacies and GPs across the country since its commercial launch last year. |
| BioBeats | Series A | $3M | Oxford Sciences Innovation, White Cloud, IQ Capital | The new capital will enable the company to scale its international offerings. | BioBeats’ primary offering is the BioBase app. The platform helps users manage their stress while tracking any long-term developments through an in-app dashboard. In addition, the app offers coaching courses to educate users on stress-related topics, such as identifying personal stress triggers. |
| Ciitizen | seed | $3M | Andreessen Horowitz’s a16z Bio Fund | The funding will support development of the platform, which recently entered a private beta. | Ciitizen’s platform will help patients collect their medical data by leveraging their rights under HIPAA. Then the platform will store the data and convert it into a usable format, making it easy to choose to share it. The goal is to open up the door for things like research and precision medicine using voluntarily shared data. |
| RDMD | seed | $3M | Lux Capital (lead), Village Global, First Round’s Healthcare Co-Op, Garuda, Shasta Ventures, other unnamed angel investors | The new funding will be directed toward platform development, leadership hires, potential research partnerships, and expansions into new diseases. | RDMD’s platform extracts and analyzes data from EHRs to conduct rapid retrospective studies and generate new real-world data. These data are housed in RDMD’s regulatory-compliant proprietary database, according to the company, and can be used by partnering biopharmaceuticals or research groups to inform the design of future clinical trials, or support a product’s regulatory submission. |
| Zipnosis | Series B | $3M | Existing investors | The round will support Zipnosis’s “sustainable, organic growth”, according to CEO Jon Pearce | Minneapolis, Minnesota-based Zipnosis offers whitelabeled telemedicine tools to providers |
| Carepoynt | seed | $2M | undisclosed | The funding will be used for general growth. | Carepoynt’s incentive-based health and wellness platform works by first letting customers set up a free account. They can then earn points for participating in positive health behaviors like going to the doctors or the gym. It also gives people points for buying things at certain retail stores that focus on health and going to the spa, according to the company’s webpage. |
| Rx.Health | seed | $1.8M | Undisclosed | The investment will help the company pursue new clients and support the launch of its digital therapeutics and patient engagement tool, Bulk Prescription. | A spinoff of Mount Sinai Health System, Rx.Health builds app prescription platforms for enterprises. |
| TestCard | seed | $1.7M | Neo Ventures | The new money will help the company launch its UTI and pregnancy tests. | TestCard’s product is a physical postcard with an embedded, pull-out urine testing strip, along with a smartphone app that can scan the postcard and deliver a result. |
| NeuroFlow | unknown | $1.2M | NJ JumpStart (lead), Independence Blue Cross, Chestnut Street Ventures, Ben Franklin Technology Partners | The new money will be used to help further its primary platform offering through product development and sales hires. | NeuroFlow’s offerings combine a range of mental healthcare resources and management tools within a single cloud-based platform. |
| PatientWisdom | Series A | $1M | OCA Ventures, others | These funds will help PatientWisdom increase increase sales capabilities and bring its tool to market. | PatientWisdom is a digital health company specializing in real-world data collection tools. |
| Bot M.D. | seed | $700,000 | Y Combinator, angels including Steve Blank | The funding will support the app’s burgeoning rollout and continue to make the AI smarter. | Bot M.D. is meant to be an alterantive source of information for doctors, primarily the information they need in the course of their work like drug interactions, medical calculators, some guidelines and protocols, and information on less common diseases. Doctors can even use it to find medical images and videos. The app uses artificial intelligence to present this information in the form of a personable and even humorous chatbot. |
| Freeletics | unknown | undisclosed | Courtside Ventures, Elysian Park Ventures, Causeway Media Partners, JAZZ Venture Partners, ward.ventures | The company will use the new money to go deeper into the US market | Freeletics is a European online fitness startup that uses AI to create personalized fitness plans. |